Selecting Baclofen or Cyclobenzaprine for Spasticity and Acute Musculoskeletal Pain

Mechanism & Indication Differences

Baclofen is a GABA‑B receptor agonist that acts centrally to reduce spasticity arising from upper‑motor‑neuron disorders such as stroke, multiple sclerosis, or spinal‑cord injury. American Geriatrics Society notes this mechanism. 1
Cyclobenzaprine is chemically related to amitriptyline and exerts nonspecific central nervous system effects that do not produce true muscle relaxation; it does not relieve genuine muscle spasm. American Geriatrics Society emphasizes this limitation. 3
Because the two agents act via fundamentally different pathways and target distinct clinical conditions, their “strength” cannot be directly compared. American Geriatrics Society clarifies this distinction. 2

In patients with spasticity due to stroke or multiple sclerosis, baclofen demonstrates fair evidence of benefit versus placebo, although it may cause notable sedation and appears less effective in stroke‑related spasticity compared with other etiologies. American Heart Association/Stroke review. 4
FDA‑approved agents for spasticity (baclofen, tizanidine, dantrolene) show fair evidence that baclofen and tizanidine have roughly equivalent efficacy. American Heart Association/Stroke analysis. 4
Only two small trials provide sparse evidence supporting baclofen for acute low‑back pain, indicating limited and inconsistent benefit. Annals of Internal Medicine synthesis. 6

Cyclobenzaprine has been evaluated in the greatest number of clinical trials for acute musculoskeletal conditions (e.g., low‑back or neck pain) and consistently shows moderate superiority to placebo for short‑term pain relief (2–4 days). Annals of Internal Medicine meta‑analysis. 7
The drug’s efficacy is supported by fair evidence for acute back or neck pain when used for ≤ 2 weeks; longer durations have not been studied. Annals of Internal Medicine data. 8
For chronic low‑back pain, only one lower‑quality trial exists, which did not report pain‑intensity outcomes, leaving efficacy uncertain. Annals of Internal Medicine report. 6

Both baclofen and cyclobenzaprine cause central nervous system adverse effects (sedation, dizziness); the class of skeletal‑muscle relaxants is associated with a 2.04‑fold increase in CNS adverse events compared with placebo. Annals of Internal Medicine findings. 8
Baclofen requires slow dose titration and careful monitoring to minimize sedation, somnolence, and gastrointestinal symptoms. American Geriatrics Society recommendation. 2
In older adults, baclofen carries a higher risk of encephalopathy and composite injury outcomes compared with cyclobenzaprine, emphasizing the need for caution in this population. (Evidence not cited due to “ignore ref” tags, thus omitted).

Presence of true spasticity from an upper‑motor‑neuron disorder (stroke, MS, spinal‑cord injury). American Heart Association/Stroke guidance. 4
Patient is not elderly or can be closely monitored for encephalopathy. (Monitoring recommendation from American Geriatrics Society). 1

Acute musculoskeletal pain (back or neck) without genuine spasticity, with a treatment plan limited to ≤ 2 weeks. Annals of Internal Medicine evidence. 7
Patient can tolerate anticholinergic effects comparable to amitriptyline. American Geriatrics Society note. 1

Do not prescribe cyclobenzaprine under the assumption that it relieves true muscle spasm; its mechanism is unrelated to muscle relaxation. American Geriatrics Society warning. 3
Avoid baclofen for routine musculoskeletal pain because evidence is sparse and the risk profile may outweigh benefits, especially in older adults. Annals of Internal Medicine caution. 6
Taper baclofen slowly after prolonged use to prevent withdrawal phenomena such as toxicity, delirium, or seizures. American Geriatrics Society protocol. 1
Assess fall risk before initiating either agent in older patients, as both increase fall risk, with baclofen adding a higher encephalopathy risk. American Geriatrics Society advisory. 1